GlassScriptPhysician profile
Bradley W Greider
NPI 1508979006
$6,122.10
in general payments reported to CMS, 2019-2025
27 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $823 · 2021: $1,120 · 2022: $565 · 2023: $858 · 2024: $358 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.32 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $1,369.30 | 2022-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Alcon Vision LLC | $492.52 | 2019-2025 | Clareon, Rocklatan |
| Allergan, INC. | $477.45 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $452.16 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Glaukos Corporation | $406.26 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $396.48 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $380.55 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Mallinckrodt Hospital Products INC. | $331.36 | 2020-2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $291.96 | 2019-2021 | |
| Abbvie INC. | $275.09 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $274.60 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $236.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $208.40 | 2019-2022 | |
| Oyster Point Pharma, INC. | $109.46 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $82.02 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $55.45 | 2019 | |
| Horizon Therapeutics Plc | $47.63 | 2022-2023 | Tepezza |
| Harrow Eye, LLC | $43.26 | 2024-2025 | Vevye |
| Thea Pharma INC. | $37.97 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $28.17 | 2022 | |
| Alcon Research LLC | $25.87 | 2019 | |
| Ivantis, INC | $24.69 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.13 | 2019 | |
| Biotissue Holdings INC. | $20.12 | 2022 | |
| Eyevance Pharmaceuticals LLC | $18.37 | 2023 | Flarex |
| Sight Sciences, INC. | $13.49 | 2025 | Omni Surgical System |
| New World Medical,INC. | $1.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Greider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.